Objective: Assessment of patient preferences for attributes of asthma treatments.
Methods: Two hundred ninety-eight patients (age range, 18 to 60 years) from 15 centers in Sweden completed a questionnaire concerning their asthma, and ranked 18 alternative treatments using conjoint analysis. Patients were receiving treatment with either inhaled corticosteroids (ICS) and short-acting bronchodilator (n = 123) or ICS and long-acting bronchodilator (separate inhalers, n = 87; combination inhaler, n = 88). Attributes analyzed were maintenance treatment, additional reliever, time to onset and duration of reliever, number of symptom-free days (SFDs) per month, and out-of-pocket cost per month.
Results: Conjoint analysis showed that the most important aspect of treatment was SFD. Forty percent of the patients had
Conclusion: SFDs were the most important attribute in asthma treatment. Patients were willing to pay for a switch to their preferred treatment. The most favored treatments were a reliever therapy that is both rapid and long acting and a combination inhaler for both maintenance and as-needed use.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1378/chest.125.3.916 | DOI Listing |
Arthritis Rheumatol
May 2017
Istituto Giannina Gaslini, Pediatria II - Reumatologia, PRINTO, Genoa, Italy.
Objective: To develop response criteria for juvenile dermatomyositis (DM).
Methods: We analyzed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. They were further validated using data from the PRINTO trial of prednisone alone compared to prednisone with methotrexate or cyclosporine and the Rituximab in Myositis (RIM) trial.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!